食管癌疫苗临床应用分析

刘东红; 朱丽华; 张庆波; 曹秀华; 石恩富; 丁贺田

doi:10.3969/j.issn.1000-8179.20141175

食管癌疫苗临床应用分析

doi: 10.3969/j.issn.1000-8179.20141175

刘东红^{①, ②,},
朱丽华^①, ,,
张庆波^①,
曹秀华^②,
石恩富^②,
丁贺田^③

①.
河北联合大学基础医学院病原生物与免疫学学科(河北省唐山市063000)
②.
遵化市第二医院外科(河北省唐山市063000)
③.
遵化市民族医院肿瘤外科(河北省唐山市063000)

基金项目:

河北省科学技术厅项目 09276418D-18

唐山市科技计划指令项目 132777138

详细信息

作者简介:
刘东红专业方向为肿瘤免疫及生物治疗。E-mail：zqb1955@163.com

通讯作者:
朱丽华 zhulihua1972@163.com

计量
- 文章访问数: 32
- HTML全文浏览量: 15
- PDF下载量: 4
- 被引次数: 0
出版历程
- 收稿日期: 2014-07-14
- 修回日期: 2014-10-19
- 刊出日期: 2020-12-29

Analysis of the effect of clinical application of vaccine for esophageal cancer

LIU Donghong^{①, ②
,},
ZHU Lihua^{①
, ,},
ZHANG Qingbo^①,
CAO Xiuhua^②,
SHI Enfu^②,
DING Hetian^③

①.
Department of Pathogenic Organism and Immunology, Hebei United University, Tangshan 063000, China
②.
Department of Surgical Oncology, Zunhua No. 2 Hospital, Zunhua 064200, China
③.
Department of Surgical Oncology, Zunhua National Hospital, Zunhua 064206, China

Funds:

The Science and Technology Support Program of Hebei Province 09276418D-18

The Science and Technology Support Program of Hebei Province 132777138

More Information

Corresponding author: Lihua ZHU; E-mail: zhulihua1972@163.com

摘要

摘要: 目的对食管癌疫苗在临床应用效果进行分析，以期为临床应用提供参考。方法从食管癌术后肿瘤组织标本中提取其可溶性抗原成分和超抗原SEC构建成肿瘤疫苗，对食管癌术后328例患者进行临床应用(观察组)，并以常规治疗326例患者作为对照组，观察并分析临床应用效果和5年随访结果。结果观察组5年生存率为49.71%(173/328)，对照组5年生存率为20.55% (67/326)，经统计学处理有显著性差异(P < 0.05)；女性生存率为51.22% (84/164)，男性生存率为45.12% (74/164)，女性生存率显著高于男性(P < 0.05)。观察组中低分化患者的生存率(61.90%)显著高于高分化患者的生存率(41.61%)，差异具有统计学意义(P < 0.05)；而对照组低分化患者生存率(10.75%)显著低于高分化患者的生存率(31.34%)，差异具有统计学意义(P < 0.05)。结论该疫苗能有效防止食管癌术后患者的复发和肿瘤转移，提高生存率，特别是对女性患者和恶性程度高的患者效果更佳。
- 肿瘤疫苗 /
- 食管癌 /
- 肿瘤可溶性抗原 /
- 超抗原SEC /
- 生物治疗
Abstract: Objective To analyze the effects of the clinical applications of vaccine for esophageal cancer to provide treatment basis. Methods Tumor-soluble antigen was extracted from clinical samples of esophageal cancer tissue. Vaccine for esophageal cancer was prepared using antigen and superantigen staphylococcal enterotoxin C (SEC). One group of patients with esophageal cancer was treated with vaccine after surgery (treatment group). Another group of patients with esophageal cancer was treated using routine methods (control group). After five years, the patients were followed up to analyze survival. Results After five years of follow up, the survival rates of treatment and control groups were 173/328 (49.71%) and 67/326 (20.55%), respectively. Survival rates significantly differed between the two groups (P < 0.05). Furthermore, the survival rates of the female patients were higher than those of the male patients (P < 0.05). In the treatment group, the survival rates of patients with low-differentiation cancer were higher than those of patients with high-differentiation cancer (P < 0.05). In the control group, the survival rates of patients with low-differentiation cancer were lower than those of patients with high-differentiation cancer (P < 0.05). Conclusion Tumor vaccine prepared with esophageal cancer antigen and superantigen SEC could increase the survival rate of patients with esophageal cancer, particularly female patients and those with low-differentiation cancer.
- tumor vaccine /
- esophageal cancer /
- tumor-soluble antigen /
- superantigen SEC /
- tumor biotherapy

HTML全文

表 1 观察组和对照组5年生存情况比较例(%)

Table 1. Comparison of five-year survival rate between treatment and control groups [case (%)]

表 2 肿瘤分化程度与生存率的卡方分析例(%)

Table 2. Analysis between the degree of tumor differentiation and the survival rate [case (%)]

表 3 不同分化程度的肿瘤抗原对PBMC增殖活性影响的比较(OD值，x±s)

Table 3. Peripheral blood mononuclear cell proliferation stimulated by the tumor antigen of different groups(OD value, x±s)

参考文献(12)

[1]	刘奇, 刘会宁, 彭忠民.主编.实用胸部肿瘤外科学[M].北京: 军事医学科学出版社, 2007: 338-339. Liu Q, Liu HN, Peng ZM. Practical study of thoracic tumor surgery[M]. Beijing: Military Medical Science Press, 2007: 338-339.
[2]	张国良, 主编.实用胸部外科学[M].北京: 中国医药科技出版社, 2007: 750-753. Zhang GL. The utility of thoracic surgery[M]. Beijing: China pharmaceutical science and Technology Publishing House, 2007: 750-753.
[3]	李进东, 王文光, 许金良, 等.胸段食管癌淋巴结转移特点的研究[J].中华医学杂志, 2006, 86(45):3297-3200. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyx200645008 Li JD, Wang WG, Xu JL, et al. Characteristics of lymphnode metastasis in thoracic esophageal carcinoma[J]. Natl Med J China, 2006, 86(45):3297-3200. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyx200645008
[4]	马淑芹, 郑全辉, 张庆波, 等.食管癌疫苗抗癌机理研究[J].中国肿瘤临床, 2012, 39(24):2066-2069. doi: 10.3969/j.issn.1000-8179.2012.24.020 Ma SQ, Zheng QH, Zhang QB, et al. Anticancer mechanism of esophagus cancer vaccine[J]. Chin J Clin Oncol, 2012, 39(24): 2066-2069. doi: 10.3969/j.issn.1000-8179.2012.24.020
[5]	Patterson KG, Dixon Pittaro JL, Bastedo PS, et al. Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 Oncofetal Antigen[J]. Int J Cancer, 2014, 115(4):591-598.
[6]	Hutten T, Thordardottir S, Hobo W, et al. Ex Vivo Generation of Interstitial and langerhans cell-like dendritic cell Subset-based Vaccines for Hematological Malignancies[J]. J Immunother. 2014, 37(5): 267-277. doi: 10.1097/CJI.0000000000000035
[7]	李树义, 刘洪梅, 张庆波, 等.肿瘤可溶性抗原联合金葡素超抗原共同诱导杀瘤细胞的实验研究[J].中国临床医学, 2011, 18(1):22-24. doi: 10.3969/j.issn.1008-6358.2011.01.007 Li SY, Liu HM, Zhang QB, et al. Study on Tumor-Killing Cells Induced by Esophageal Cancer Antigen and Staphlococcal Enterotoxin[J]. Chinese Journal of Clinical Medicine, 2011, 18(1):22-24. doi: 10.3969/j.issn.1008-6358.2011.01.007
[8]	张庆波, 么文博, 徐卫国, 等.可溶性抗原联合超抗原诱导的CTL抗瘤作用的实验研究[J].现代肿瘤医学, 2012, 20(7):1341-1343. doi: 10.3969/j.issn.1672-4992.2012.07.07 Zhang QB, Yao WB, Xu WG, et al. Anti-tumor effect of CTL induced by tumor soluble antigen and superantigen SEC[J]. Modern Oncology, 2012, 20(7):1341-1343. doi: 10.3969/j.issn.1672-4992.2012.07.07
[9]	刘洪梅, 张晓群, 刘亚楠, 等.胶质瘤抗原联合超抗原SEC诱导杀瘤性免疫细胞的实验研究[J].中国肿瘤临床, 2011, 38(6):301-303. http://journal11.magtechjournal.com/Jwk_zgzllc/CN/abstract/abstract8584.shtml Liu HM, Zhang XQ, Liu YN, et al. Induetion of Tumor-killing Immune Cells by Glioma Antigen and Superantigen SEC[J]. Chin J Clin Oncol, 2011, 38(6):301-303. http://journal11.magtechjournal.com/Jwk_zgzllc/CN/abstract/abstract8584.shtml
[10]	Hahnel PS, Thaler S, Antunes E, et al. Targeting AKT signaling sensitizes cancer to cellular immunotherapy[J]. Cancer Res, 2008, 68 (10):3899-3906. doi: 10.1158/0008-5472.CAN-07-6286
[11]	Bronte V, Mocellon S. Suppressive influences in the immune response to cancer[J]. J immunother, 2009, 32(1):1-11. doi: 10.1097/CJI.0b013e3181837276
[12]	Liu Z, Kim JH, Falo LD, et al. Tumor regulatory T cells potently abrogate antitumor immunity[J]. J Immunol, 2009, 182(10):6160-6167. doi: 10.4049/jimmunol.0802664